Histogen and Amerimmune Report Publication on Emricasan in COVID-19

Histogen Inc. and its partner, Amerimmune, LLC,  recently reported the publication of the potential utility of Emricasan in COVID-19 in Allergy, the official Journal of the European Academy of Allergy and Clinical Immunology.

Amerimmune, in collaboration with Dr. Raavi Gupta from SUNY Downstate Medical Center and Dr. Lishomva Ndhlovu from Weill Cornell Medicine, demonstrated the impact of caspases in multiple blood cells beyond the acute stage of the disease. 

The research paper entitled “Caspases in Moderate-Severe, Long COVID-19 Disease and the Therapeutic Potential of Caspase Inhibitors” has been published in Allergy, the Journal of the European Academy of Allergy and Clinical Immunology, and is currently available electronically at https://onlinelibrary.wiley.com/doi/10.1111/all.14907

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.

About Ammerimmune

Amerimmune LLC is a research center and immunology laboratory with a strong focus on identifying underlying mechanisms of immune disorders. Amerimmune’s mission is to bring relevant science, data, and diagnostic and therapeutic solutions to diseases that involve the immune system. For more information and to explore partnering opportunities, please visit www.amerimmune.com.

About the CIIC

The CIIC is a professional medical organization formed in 2013 and comprised of select Board Certified Immunologists in private practice throughout the USA. We provide high quality care for patients with Primary Immune Deficiency Disorders (PIDD), promote access to treatment, serve as advocates to patients and physicians who care for PIDD patients and participate in research that benefits patient care.

CIIC Mission – Provide cutting edge therapy to patients with Primary Immune Deficiency

CONTACT

PHONE:
Lyn Lewars
817.701.5609

WEBSITE:
https://ciiclinics.org/

EMAIL:
[email protected]